Teyi Pharmaceutical Group Co.Ltd(002728) april 22 announced that Hainan Haili Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently obtained the notice of approval for drug supplementary application for “metformin hydrochloride sustained release tablets” approved and issued by the State Drug Administration. After review, the drug passed the consistency evaluation of the quality and efficacy of chemical imitation drugs.
Metformin is the first choice for diabetic patients. It has hypoglycemic effect and insulin resistance. The main dosage form listed outside China is tablets, and sustained-release tablets can significantly reduce gastrointestinal adverse reactions after taking drugs, reduce the times of taking drugs every day, and improve drug safety and compliance.
The passing of this consistency evaluation is the embodiment of the company’s comprehensive strength such as R & D capacity, production and quality management system, as well as the recognition of the company’s comprehensive strength and product quality by the national drug regulatory department. It provides important valuable experience for the company’s subsequent varieties to pass the consistency evaluation, has a positive impact on the company, is conducive to the company’s participation in centralized procurement bidding, improves the product market competitiveness and expands the product market share. (Huang Shu)
